Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
Morris MJ; Pandit-Taskar N; Carrasquillo J; Divgi CR; Slovin S; Kelly WK; Rathkopf D; Gignac GA; Solit D; Schwartz L; Stephenson RD; Hong C; Delacruz A; Curley T; Heller G; Jia X; O'Donoghue J; Larson S; Scher HI; Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology, 2009, vol. 27, issue 15, p 2436, ISSN 15277755. ISBN 15277755.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef